← back to search

Devi SenGupta

Gilead Sciences (United States) · US
Area of research
Infectious Diseases · Virology
Research interest
Research interests include HIV Research and Treatment, HIV/AIDS drug development and treatment, HIV/AIDS Research and Interventions, and HIV-related health complications and treatments.
h-index
28
citations
5,564
works
89
NIH funding
primary concept
Medicine
email

Recent publications

Correlates of HIV-1 control after combination immunotherapy
Nature 2025cited by 21position: middledoi
Early Viral Dynamics Predict Human Immunodeficiency Virus Posttreatment Control After Analytic Treatment Interruption
The Journal of Infectious Diseases 2024cited by 3position: middledoi
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021
Nature Medicine 2021cited by 362position: middledoi
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy
Science Translational Medicine 2021cited by 78position: firstdoi
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
New England Journal of Medicine 2020cited by 1,436position: middledoi
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
JAMA 2020cited by 1,274position: middledoi
Multi-stakeholder consensus on a target product profile for an HIV cure
The Lancet HIV 2020cited by 78position: middledoi
Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus–1
Clinical Infectious Diseases 2020cited by 74position: lastdoi
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
The Lancet 2017cited by 392position: middledoi
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial
The Lancet HIV 2016cited by 41position: middledoi
The CD8 <sup>+</sup> Memory Stem T Cell (T <sub>SCM</sub> ) Subset Is Associated with Improved Prognosis in Chronic HIV-1 Infection
Journal of Virology 2014cited by 60position: lastdoi
Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection
Retrovirology 2014cited by 53position: middledoi
HERV-K–specific T cells eliminate diverse HIV-1/2 and SIV primary isolates
Journal of Clinical Investigation 2012cited by 95position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Steven G. Deeks · University of California, San Francisco5 papers (2014–2024)Romas Geleziunas · Gilead Sciences (United States)3 papers (2020–2024)Edwin DeJesus · Orlando Immunology Center3 papers (2017–2021)Terri Wrin · LabCorp (United States)2 papers (2020–2021)Frederick Hecht · University of California, San Francisco2 papers (2014–2024)John W. Mellors · University of Pittsburgh2 papers (2020–2021)Cynthia Brinson · Brown University2 papers (2020–2021)Jeffrey J. Wallin · Gilead Sciences (United States)2 papers (2020–2021)Douglas F. Nixon · Northwell Health2 papers (2014–2014)Elena Vendrame · Gilead Sciences (United States)2 papers (2021–2024)Moti Ramgopal · Indiana University – Purdue University Indianapolis2 papers (2020–2021) · 2 papers (2020–2021)Liao Zhang · Gilead Sciences (United States)2 papers (2020–2021)Diana M. Brainard · Gilead Sciences (France)2 papers (2020–2021)Susan Guo · Gilead Sciences (United States)2 papers (2020–2021)Jeffrey M. Milush · University of California, San Francisco2 papers (2014–2021)Rebecca Begley · Gilead Sciences (United States)2 papers (2020–2021)Erin Quirk · Gilead Sciences (United States)2 papers (2016–2017)Rita Humeniuk · Center for Cancer Research2 papers (2020–2021)Jana L. Jacobs · Center for Cancer Research1 papers (2020–2020)